GILD / Gilead Sciences, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 10, 2025 GILEAD SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 10, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fil

Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants commencing in 2025)

EXHIBIT 10.20 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B.This Stock Option Agreement (this “Agr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exac

Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grants commencing in 2025)

EXHIBIT 10.33 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 7, 2025 GILEAD SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 7, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 30, 2025 GILEAD SCIENCES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 30, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

Amended and Restated Bylaws of Registrant

EXHIBIT 3.1 Gilead Sciences, Inc. Amended and Restated Bylaws (as of July 30, 2025) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 (a) Advance Notice of Stockholder Business 1 (b) Advance Notice

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 7, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No

Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2025)

EXHIBIT 10.22 TSR PERFORMANCE GOAL GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Performance Share Award Agr

Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants commencing in 2025)

EXHIBIT 10.30 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit Agreement (this “Agre

Form of performance share award agreement – Adjusted EPS Growth Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2025)

EXHIBIT 10.25 ADJUSTED EPS GROWTH PERFORMANCE GOAL GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Performance

Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants commencing in 2025)

EXHIBIT 10.13 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Global Stock Option Agreement (this “Agreement”) is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 24, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.

This is not a solicitation of authority to vote your proxy. Please DO NOT send us your proxy card as it will not be accepted

Notice of Exempt Solicitation NAME OF REGISTRANT: Gilead Sciences, Inc NAME OF PERSON RELYING ON EXEMPTION: Mercy Investment Services ADDRESS OF PERSON RELYING ON EXEMPTION: 2039 N Geyer Rd, Frontenac, MO 63131 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934.

Letter from Our Chairman and Chief Executive Officer Letter from Our Lead Independent Director Notice of Annual Meeting of Stockholders Table of Contents Overview Proxy Voting Roadmap Corporate Governance Audit Matters Audit Committee Report Executiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

GILEAD SCIENCES, INC. - DEF A14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 9, 2025 GILEAD SCIENCES, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 9, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-19731 GILEAD SCIENCES, I

Insider Trading Policy

EXHIBIT 19.1 GILEAD SCIENCES, INC. INSIDER TRADING POLICY TABLE OF CONTENTS 1.0INTRODUCTION 2.0OBJECTIVES 3.0BACKGROUND 3..1PURPOSES 3..2IMPORTANT DEFINITIONS 3..3PENALTIES AND SANCTIONS 4.0TRADING BY COVERED PERSONS 5.0POLICY STATEMENTS 6.0PROCEDURES 1.0 INTRODUCTION The Common Stock, par value $.001 per share (the “Common Stock”), of Gilead Sciences, Inc. (together with its subsidiaries, the “Co

Subsidiaries of Registrant

Exhibit 21.1 SUBSIDIARIES OF GILEAD SCIENCES, INC. (as of December 31, 2024) NAME OF SUBSIDIARY COUNTRY OF FORMATION Asegua Therapeutics LLC United States CymaBay Therapeutics, Inc. United States Forty Seven, LLC United States Forty Seven Holdings, LLC United States Gilead Alberta, LLC United States Gilead Apollo, LLC United States Gilead Biopharmaceutics US LLC United States Gilead Calistoga, LLC

Arcus Biosciences, Inc. Lock-Up Agreement February 17, 2025 Goldman Sachs & Co. LLC Leerink Partners LLC As Representatives of the several Underwriters named in Schedule I to the Underwriting Agreement c/o Goldman Sachs & Co. LLC 200 West Street New

EX-99.1 3 lockupagreement.htm LOCK-UP AGREEMENT Exhibit 99.1 Arcus Biosciences, Inc. Lock-Up Agreement February 17, 2025 Goldman Sachs & Co. LLC Leerink Partners LLC As Representatives of the several Underwriters named in Schedule I to the Underwriting Agreement c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o Leerink Partners LLC 53 State St Boston, MA 02110 Re: Arcus Biosc

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024 Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 11, 2025 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission

SEPARATION AGREEMENT 7 January 2025 by and between GALAPAGOS NV GILEAD THERAPEUTICS A1 UNLIMITED COMPANY GILEAD SCIENCES INC. Parent Investor

Exhibit 99.4 Private and Confidential Execution copy CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[…***…]” BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SEPARATION AGREEMENT dated 7 January 2025 by and between GALAPAGOS NV Company and GILEAD THERAPEUTICS A1 UNLIMITED COMPANY Investor and GILEAD SCIENCES INC

Directors and Executive Officers of Gilead

Exhibit 99.3 Directors and Executive Officers of Gilead All addresses are c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California, 94404. Name Title Citizenship Principal Occupation Daniel P. O’Day Chief Executive Officer, Chairman and Director United States * Jacqueline K. Barton, Ph.D. Director United States Professor Emerita, California Institute of Technology Jeffrey A. Blueston

The name and present principal occupation of each of the executive officers and directors of Gilead Sciences, Inc. are set forth below. Unless otherwise noted, each of these persons have as their business address c/o Gilead Sciences, Inc., 333 Lakesi

Exhibit 99 The name and present principal occupation of each of the executive officers and directors of Gilead Sciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 17, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fil

GILEAD SCIENCES APPOINTS DIETMAR BERGER, MD, PHD, AS CHIEF MEDICAL OFFICER

Exhibit 99.1 CONTACTS: Ashleigh Koss, Media [email protected] Jacquie Ross, Investors [email protected] GILEAD SCIENCES APPOINTS DIETMAR BERGER, MD, PHD, AS CHIEF MEDICAL OFFICER Foster City, Calif., Dec. 12, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become

Underwriting Agreement, dated November 13, 2024, among the Company and Barclays Capital Inc. and BofA Securities, Inc., as representatives of the several underwriters listed in Schedule 1 thereto.

Exhibit 1.1 Execution Version GILEAD SCIENCES, INC. Underwriting Agreement November 13, 2024 Barclays Capital Inc. BofA Securities, Inc. as Representatives of the several Underwriters listed in Schedule 1 hereof c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Gilead Sciences, Inc., a Dela

Tenth Supplemental Indenture, dated as of November 20, 2024, between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee (including Form of 2029 Note, Form of 2035 Note, Form of 2054 Note and Form 2064 Note)

Exhibit 4.2 TENTH SUPPLEMENTAL INDENTURE GILEAD SCIENCES, INC. AND COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO WELLS FARGO BANK, NATIONAL ASSOCIATION, AS TRUSTEE Tenth Supplemental Indenture Dated as of November 20, 2024 Supplementing the Indenture Dated as of March 30, 2011 4.80% Senior Notes due 2029 5.10% Senior Notes due 2035 5.50% Senior Notes due 2054 5.60% Senior Note

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 20, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission F

Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables S-3 GILEAD SCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Dat

Gilead Sciences, Inc. $3,500,000,000 $750,000,000 4.80% Senior Notes due 2029 $1,000,000,000 5.10% Senior Notes due 2035 $1,000,000,000 5.50% Senior Notes due 2054 $750,000,000 5.60% Senior Notes due 2064

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(5)  Registration No. 333-273745 Prospectus Supplement (To Prospectus dated August 4, 2023) Gilead Sciences, Inc. $3,500,000,000 $750,000,000 4.80% Senior Notes due 2029 $1,000,000,000 5.10% Senior Notes due 2035 $1,000,000,000 5.50% Senior Notes due 2054 $750,000,000 5.60% Senior Notes due 2064 We are offering $750,000,000 aggregate principal amount

Subject to Completion, dated November 13, 2024

TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed.

GILEAD SCIENCES, INC. PRICING TERM SHEET 4.80% SENIOR NOTES DUE 2029 5.10% SENIOR NOTES DUE 2035 5.50% SENIOR NOTES DUE 2054 5.60% SENIOR NOTES DUE 2064

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-273745 November 13, 2024 GILEAD SCIENCES, INC. PRICING TERM SHEET 4.80% SENIOR NOTES DUE 2029 5.10% SENIOR NOTES DUE 2035 5.50% SENIOR NOTES DUE 2054 5.60% SENIOR NOTES DUE 2064 Issuer: Gilead Sciences, Inc. (the “Company”) Title of Security: 4.80% Senior Notes due 2029 (the “2029 Notes”) 5.10% Senior Notes due 2035

Transition Services and General Release Agreement for Merdad Parsey, dated July 16, 2024

EXHIBIT 10.51 Delivery Date: July 16, 2024 Merdad Parsey Re: Transition Services and General Release Agreement Dear Merdad: This Transition Services and General Release Agreement (this “Transition Agreement”), which provides for a Supplemental Release (together with the general release herein, the “Releases,” and this Transition Agreement and the Supplemental Release together, the “Agreement”), co

Gilead Sciences, Inc. Severance Plan, amended and restated August 1, 2024

EXHIBIT 10.41 GILEAD SCIENCES, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (As Amended and Restated Effective August 1, 2024) I.INTRODUCTION The Gilead Sciences, Inc. Severance Plan (the “Plan”) was originally adopted by the Company effective January 29, 2003, and was subsequently amended and restated on May 9, 2006, May 8, 2007, in February, May and December 2008, in December 2009, in Januar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC.

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion Oncology Sales Increased 6% Year-Over-Year to $816

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 6, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fi

Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grants commencing in 2024)

EXHIBIT 10.37 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.7 billion Biktarvy Sales Increased 8% Year-Over-Year to $3.2 billion Oncology Sales Increased 15% Year-Over-Year to $841

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 8, 2024 GILEAD SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 8, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Ex

Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants commencing in 2024)

EXHIBIT 10.18 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B.This Stock Option Agreement (this “Agr

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 17, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

CHIEF MEDICAL OFFICER MERDAD PARSEY TO LEAVE GILEAD EARLY 2025

Exhibit 99.1 CONTACTS: Ashleigh Koss, Media [email protected] Jacquie Ross, Investors [email protected] CHIEF MEDICAL OFFICER MERDAD PARSEY TO LEAVE GILEAD EARLY 2025 Foster City, Calif., July 17, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identif

ASMB / Assembly Biosciences, Inc. / GILEAD SCIENCES INC Activist Investment

SC 13D/A 1 s13da061724-assemblybio.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 8, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No

Restated Certificate of Incorporation of Registrant

Exhibit 3.2 RESTATED CERTIFICATE OF INCORPORATION OF GILEAD SCIENCES, INC. Daniel P. O’Day hereby certifies as follows: FIRST: The original name of the corporation was Oligogen, Inc. and the date of filing of the original Certificate of Incorporation with the Secretary of State of the State of Delaware was June 22, 1987. SECOND: He is duly elected and acting Chief Executive Officer of Gilead Scien

Certificate of Amendment of Restated Certificate of Incorporation of Gilead Sciences, Inc., as amended May 9, 2024

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF GILEAD SCIENCES, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Gilead Sciences, Inc. (the “Corporation”), a Delaware corporation, does hereby certify as follows: FIRST: Paragraph (A) of Article IV of the Corporation’s Restated Certificate of Incorporation is hereby amended to rea

Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants commencing in 2024)

EXHIBIT 10.35 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit Agreement (this “Agre

Form of performance share award agreement - Revenue Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2024)

EXHIBIT 10.27 REVENUE PERFORMANCE GOAL GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Performance Share Award

Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2024)

EXHIBIT 10.22 TSR PERFORMANCE GOAL GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Performance Share Award Agr

Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants commencing in 2024)

EXHIBIT 10.12 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Global Stock Option Agreement (this “Agreement”) is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exa

AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D

EX-99.1 2 d829072dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned hereby agree to the joint filing on behalf of each of them of Amendment No. 3 to the Schedule 13D (including any and all further amendments thereto) with respect to the Ordinary Shares of Galapagos NV and further agree that this Joint Filing Agreement shall be included as an Exhibi

SUBSEQUENT GILEAD WARRANT B – issued by – GALAPAGOS NV – dated – [date] 2024

EX-99.2 3 d829072dex992.htm EX-99.2 Exhibit 99.2 SUBSEQUENT GILEAD WARRANT B – issued by – GALAPAGOS NV – dated – [date] 2024 TABLE OF CONTENT Articles Page 1. Certain Definitions and Interpretation 1 1.1.  Certain definitions 1 1.2.  Headings 3 1.3.  Meaning of references 4 1.4.  Fractional value of Shares 4 1.5.  Language 4 2. Issuance, Nature and Form of the Warrant 5 2.1.  Issuance and nature

GLPG / Galapagos NV - Depositary Receipt (Common Stock) / GILEAD SCIENCES INC - SC 13D/A Activist Investment

SC 13D/A 1 d829072dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* GALAPAGOS NV (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 36315X101 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California, 94404 650-574-3000 (Name, Address and Telephone

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 25, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

LPTX / Leap Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment

SC 13G 1 d791510dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Leap Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 52187K101 (CUSIP Number) April 10, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap

XLO / Xilio Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Xilio Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 98422T100 (CUSIP Number) March 27, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

Letter from Our Chairman and Chief Executive Officer Letter from Our Lead Independent Director Notice of Annual Meeting of Stockholders Table of Contents Overview Proxy Voting Roadmap Audit Matters Audit Committee Report Executive Officers Executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

COURTESY PDF OF PROXY STATEMENT

2024 Notice of Annual Meeting of Stockholders and Proxy StatementOUR VISION To create a healthier world for all people OUR MISSION To discover, develop and deliver innovative therapeutics for people with life-threatening diseases OUR CORE VALUES Integrity Doing What’s Right STRATEGIC PRIORITIES (Refreshed in 2023) ◃ Maximize Near-Term Revenue Growth ◃ Maximize Impact of Long-acting HIV Therapies ◃

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) CYMABAY THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.

GILEAD SCIENCES ANNOUNCES COMPLETION OF ACQUISITION OF CYMABAY Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases

Exhibit 99.1 CONTACTS: Investors: Jacquie Ross investor [email protected] Media: Ashleigh Koss public [email protected] GILEAD SCIENCES ANNOUNCES COMPLETION OF ACQUISITION OF CYMABAY Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases FOSTER CITY, Calif. – March 22, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 22, 2024 GILEAD SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 22, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) CYMABAY THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.

Letter from Our Chairman and Chief Executive Officer Letter from Our Lead Independent Director Notice of Annual Meeting of Stockholders Table of Contents Overview Proxy Voting Roadmap Audit Matters Audit Committee Report Executive Officers Executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) CYMABAY THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MARCH 10, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

Press Release of Parent, dated March 11, 2024, announcing the expiration of the waiting period under the HSR Act.

Exhibit (a)(5)(F) CONTACTS: Investors: Jacquie Ross [email protected] Media: Ashleigh Koss [email protected] GILEAD SCIENCES ANNOUNCES EXPIRATION OF HART-SCOTT RODINO WAITING PERIOD FOR CYMABAY TENDER OFFER FOSTER CITY, Calif., March 11, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements

CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION FILED VIA EDGAR. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS LETTER WITH A

FOIA CONFIDENTIAL TREATMENT REQUEST CONFIDENTIAL TREATMENT REQUESTED The entity requesting confidential treatment is: BY GILEAD SCIENCES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) CYMABAY THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) CYMABAY THERAPEUTICS, INC. (Name of Subject Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.

Offer to Purchase, dated as of February 23, 2024.

TABLE OF CONTENTS  Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of CymaBay Therapeutics, Inc.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) CYMABAY THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.0001 Per Share (Ti

Subsidiaries of Registrant

Exhibit 21.1 SUBSIDIARIES OF GILEAD SCIENCES, INC. (as of December 31, 2023) NAME OF SUBSIDIARY COUNTRY OF FORMATION Asegua Therapeutics LLC United States Forty Seven, Inc. United States Forty Seven Holdings, LLC United States Gilead Alberta, LLC United States Gilead Apollo, LLC United States Gilead Biopharmaceutics US LLC United States Gilead Calistoga, LLC United States Gilead Connecticut, Inc.

Form of Notice of Guaranteed Delivery.

 Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of CYMABAY THERAPEUTICS, INC.

Gilead Sciences, Inc. Compensation Recovery Policy

Exhibit 97.1 GILEAD SCIENCES, INC. COMPENSATION RECOVERY POLICY Adopted: July 26, 2023 Recoupment of Incentive-Based Compensation Gilead Sciences, Inc. (the “Company”) has adopted this compensation recovery policy as a supplement to any other compensation recovery policies in effect now or in the future at the Company. It is the policy of the Company that, in the event the Company is required to p

Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

 Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of CYMABAY THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-19731 GILEAD SCIENCES, I

Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

 Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of CYMABAY THERAPEUTICS, INC.

Form of Letter of Transmittal.

 Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of CYMABAY THERAPEUTICS, INC.

Form of Summary Advertisement, published February 23, 2024 in The Wall Street Journal.

Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

KYTX / Kyverna Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment

SC 13G 1 d665656dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.  )* Kyverna Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 501976104 (CUSIP Number) February 12, 2024 (Date of Event Which Requires Filing of this Statement) Che

Email to CymaBay employees sent by Parent on February 14, 2024 (incorporated by reference to Exhibit 99.1 on Schedule TO-C of Parent and Purchaser filed with the Securities and Exchange Commission on February 14, 2024).

Exhibit 99.1 To: Group – All CymaBay Employees From: Daniel O’Day, Chairman and CEO of Gilead Date: February 14, 2024 Subject: Message to the CymaBay Team from Daniel O’Day, CEO, Gilead Hello Everyone, I wanted to share a few words on behalf of all of us at Gilead following the announcement earlier this week. We are delighted to have reached the agreement to acquire CymaBay. We have tremendous res

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.0001 Per Share (Ti

ALVR / AlloVir, Inc. / GILEAD SCIENCES INC - SC 13G/A Passive Investment

SC 13G/A 1 d777935dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALLOVIR, INC. (Name of Issuer) Common Stock, $0.0001 per value (Title of Class of Securities) 019818103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate

TNGX / Tango Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G/A Passive Investment

SC 13G/A 1 d756953dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TANGO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap

GILD / Gilead Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01018-gileadsciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Gilead Sciences Inc Title of Class of Securities: Common Stock CUSIP Number: 375558103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to design

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 11, 2024 GILEAD SCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 11, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or other jurisdiction of incorporation) (Commission F

Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay, Parent and Purchaser (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Parent with the Securities and Exchange Commission on February 12, 2024).

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: CYMABAY THERAPEUTICS, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and PACIFIC MERGER SUB, INC., a Delaware corporation Dated as of February 11, 2024 TABLE OF CONTENTS PAGE Article 1 THE OFFER 2 Section 1.01. The Offer 2 Section 1.02. Company Actions 4 Article 2 MERGER TRANSACTION 5 Section 2.01. Merger of Purchaser in

LinkedIn announcement posted by Parent on February 12, 2024 (incorporated by reference to Exhibit 99.2 on Schedule TO-C of Parent and Purchaser filed with the Securities and Exchange Commission on February 12, 2024).

Exhibit 99.2 Gilead LinkedIn Post, February 12, 2024 #GileadNews: We announced today that we're acquiring CymaBay Therapeutics, reinforcing our long-standing commitment to liver disease. We'll continue advancing a potential therapy for primary biliary cholangitis, a rare and chronic liver disease that impairs liver function and quality of life. Read the press release and important information: htt

Agreement and Plan of Merger, dated February 11, 2024, among CymaBay Therapeutics, Inc., Gilead Sciences, Inc. and Pacific Merger Sub, Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: CYMABAY THERAPEUTICS, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and PACIFIC MERGER SUB, INC., a Delaware corporation Dated as of February 11, 2024 TABLE OF CONTENTS PAGE Article 1 THE OFFER 2 Section 1.01. The Offer 2 Section 1.02. Company Actions 4 Article 2 MERGER TRANSACTION 5 Section 2.01. Merger of Purchaser in

Joint Press Release, dated February 12, 2024.

Exhibit 99.1 CONTACTS: Gilead Investors: Jacquie Ross [email protected] Media: Ashleigh Koss [email protected] CymaBay Investors: PJ Kelleher LifeSci Advisors, LLC [email protected] Media: Arran Attridge [email protected] GILEAD SCIENCES EXPANDS LIVER PORTFOLIO WITH ACQUISITION OF CYMABAY THERAPEUTICS - Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the

Tweet posted by Parent on February 12, 2024 (incorporated by reference to Exhibit 99.1 on Schedule TO-C of Parent and Purchaser filed with the Securities and Exchange Commission on February 12, 2024).

Exhibit 99.1 Gilead Tweet (@GileadSciences), February 12, 2024 #GileadNews: We announced today that we're acquiring @CymaBay Therapeutics, reinforcing our long-standing commitment to liver disease. Read the press release and important information: http://gilead.inc/48baEtP Forward-Looking Statements This communication contains forward-looking statements related to Gilead Sciences, Inc. (“Gilead”),

Investor Relations email sent by Parent on February 12, 2024 (incorporated by reference to Exhibit 99.3 on Schedule TO-C of Parent and Purchaser filed with the Securities and Exchange Commission on February 12, 2024).

Exhibit 99.3 Good Morning – Gilead just announced (full text at end of email) a definitive agreement to acquire CymaBay Therapeutics for $4.3B ($32.50/share), which, upon closing, will further expand our Liver Disease portfolio to include an investigational, oral PPARδ agonist (seladelpar) for the treatment of primary biliary cholangitis (PBC). PBC is a progressive, inflammatory, autoimmune diseas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CYMABAY THERAPEUTICS, INC. (Name of Subject Company (Issuer)) PACIFIC MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.0001 Per Share (Ti

GILEAD SCIENCES EXPANDS LIVER PORTFOLIO WITH ACQUISITION OF CYMABAY THERAPEUTICS -- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in

Exhibit 99.1 CONTACTS: Gilead Investors: Jacquie Ross [email protected] Media: Ashleigh Koss [email protected] CymaBay Investors: PJ Kelleher LifeSci Advisors, LLC [email protected] Media: Arran Attridge [email protected] GILEAD SCIENCES EXPANDS LIVER PORTFOLIO WITH ACQUISITION OF CYMABAY THERAPEUTICS - Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 11, 2024 GILEAD SCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 11, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or other jurisdiction of incorporation) (Commission F

GILD / Gilead Sciences, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Gilead Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 375558103 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 6, 2024 GILEAD SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 6, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased Year-Over-Year by 37% for Full Year 2023 Foster City, CA, February 6, 2024 - Gilead Sciences, Inc.

TED LOVE, MD, JOINS GILEAD SCIENCES’ BOARD OF DIRECTORS

Exhibit 99.1 Gilead Contacts: Jacquie Ross, Investors [email protected] Ashleigh Koss, Media [email protected] TED LOVE, MD, JOINS GILEAD SCIENCES’ BOARD OF DIRECTORS FOSTER CITY, Calif., Feb. 1, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted Love, MD, has been appointed to the company’s Board of Directors. Dr. Love is currently chair of the Board of Directo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 1, 2024 GILEAD SCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 1, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or other jurisdiction of incorporation) (Commission Fi

Third Amended and Restated Common Stock Purchase Agreement, dated January 29, 2024 between Arcus Biosciences, Inc. and Gilead Sciences, Inc.

EX-99.1 2 tm244278d1ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL   ARCUS BIOSCIENCES, INC.   THIRD AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT   This Third Amended and Restated Common Stock Purchase Agreement (this

Amended and Restated Investor Rights Agreement dated January 29, 2024 between Arcus Biosciences, Inc. and Gilead Sciences, Inc.

Exhibit 99.2 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. AMENDED & RESTATED INVESTOR RIGHTS AGREEMENT This Amended and Restated Investor Rights Agreement (this “Agreement”) is made as of January 29, 2024 (the “Effective Date”), by and between Arcus Biosciences, Inc., a Delaware corpora

RCUS / Arcus Biosciences, Inc. / GILEAD SCIENCES INC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARCUS BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Pe

ACLX / Arcellx, Inc. / GILEAD SCIENCES INC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcellx, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03940C100 (CUSIP Number) December 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

HOOK / HOOKIPA Pharma Inc. / GILEAD SCIENCES INC - SC 13G/A Passive Investment

SC 13G/A 1 d671740dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K 100 (CUSIP Number) December 20, 2023 (Date of Event Which Requires Filing of this Statement) Check

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales Increased 33% Year-Over-Year to $769

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC.

Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated August 1, 2023

Exhibit 10.39 Gilead Sciences, Inc. Corporate Annual Incentive Plan Amended and Restated Effective as of August 1, 2023 This Gilead Sciences, Inc. Corporate Annual Incentive Plan (the “Plan”), formerly known as the Gilead Sciences Corporate Bonus Plan, has been established by Gilead Sciences, Inc. (“Gilead”) and the participating subsidiaries of Gilead, as determined by the Plan Administrator (as

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 7, 2023 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fi

ASMB / Assembly Biosciences Inc / GILEAD SCIENCES INC - SCHEDULE 13D Activist Investment

SC 13D 1 s13d102523-assemblybio.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ASSEMBLY BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 0453961080 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650

IKNA / Ikena Oncology Inc / GILEAD SCIENCES INC - OCT 2023 FILING, IKENA ONC AS ISSUER FOR GILEAD SCIENCES, THE REPORTING PERSON Passive Investment

SC 13G 1 s13g101123-gilead.htm OCT 2023 FILING, IKENA ONC AS ISSUER FOR GILEAD SCIENCES, THE REPORTING PERSON UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ikena Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45175G108 (CUSIP Number) October 11, 2023 (Date of Event which

Underwriting Agreement, dated September 7, 2023, among the Company and Barclays Capital Inc. and Citigroup Global Markets Inc., as representatives of the several underwriters listed in Schedule 1 thereto.

  Exhibit 1.1   Execution Version   GILEAD SCIENCES, INC.   Underwriting Agreement   September 7, 2023   Barclays Capital Inc. Citigroup Global Markets Inc. as Representatives of the several Underwriters listed in Schedule 1 hereof   c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019   c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013   Ladies and G

Ninth Supplemental Indenture, dated as of September 14, 2023, between the Registrant and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee (including Form of 2033 Note and Form of 2053 Note)

Exhibit 4.2 NINTH SUPPLEMENTAL INDENTURE GILEAD SCIENCES, INC. AND COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO WELLS FARGO BANK, NATIONAL ASSOCIATION, AS TRUSTEE Ninth Supplemental Indenture Dated as of September 14, 2023 Supplementing the Indenture Dated as of March 30, 2011 5.250% Senior Notes due 2033 5.550% Senior Notes due 2053 THIS NINTH SUPPLEMENTAL INDENTURE, is ente

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 14, 2023 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation or Organizati

Calculation of Filing Fee Tables (Form Type) Gilead Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5)1 (Form Type) Issuer: Gilead Sciences, Inc.

Gilead Sciences, Inc. $2,000,000,000 $1,000,000,000 5.250% Senior Notes due 2033 $1,000,000,000 5.550% Senior Notes due 2053

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration Statement No. 333-273745 Prospectus Supplement (To Prospectus dated August 4, 2023) Gilead Sciences, Inc. $2,000,000,000 $1,000,000,000 5.250% Senior Notes due 2033 $1,000,000,000 5.550% Senior Notes due 2053 We are offering $1,000,000,000 aggregate principal amount of 5.250% senior notes due 2033 (the “2033 notes”) and $1,000,000,0

GILEAD SCIENCES, INC. PRICING TERM SHEET 5.250% SENIOR NOTES DUE 2033 5.550% SENIOR NOTES DUE 2053

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-273745 September 7, 2023 GILEAD SCIENCES, INC. PRICING TERM SHEET 5.250% SENIOR NOTES DUE 2033 5.550% SENIOR NOTES DUE 2053 Issuer: Gilead Sciences, Inc. (the “Company”) Title of Security: 5.250% Senior Notes due 2033 (the “2033 Notes”) 5.550% Senior Notes due 2053 (the “2053 Notes”) Principal Amount: 2033 Notes: $1,

Subject to Completion, dated September 7, 2023

TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but is not complete and may be changed.

Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 2 DRAFT Introduction • PD-(L)1 inhibitor-based regimens have been established as the standard-of-care 1L treatment for mNSCLC,1,2 and novel combination therapies are needed to further improve o

Exhibit 99.1 Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 1 DRAFT Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study Byoung Chul Cho,1 Manuel Cobo Dols,2 Roxana Reyes Cabanillas,3 David Vicente,4 Jose Fuentes Pradera,5 Salvatore Grisanti,6 Afshin Eli Gabayan,7 Ki Hyeong Lee,8 Eun Kyung Cho,9 Sabeen Mekan,10 Farno

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 16, 2023 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fil

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

As filed with the Securities and Exchange Commission on August 7, 2023

As filed with the Securities and Exchange Commission on August 7, 2023 Registration No.

Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of the trustee under the Indenture for the Senior Debt Securities

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) ¨ Computershare Trust Company, National Association (Exact name of trustee as specified in its charter) N

Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grants

EXHIBIT 10.34 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Gilead Sciences, Inc.

As filed with the Securities and Exchange Commission on August 4, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 4, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exac

Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants made in 2023)

EXHIBIT 10.16 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B.This Stock Option Agreement (this “Agr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 3, 2023 GILEAD SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 3, 2023 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion Oncology Sales Increased 38% Year-Over-Year to $7

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.

Second Amended and Restated Common Stock Purchase Agreement, dated June 27, 2023, between Arcus Biosciences, Inc. and Gilead Sciences, Inc.

Exhibit 99.1 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL ARCUS BIOSCIENCES, INC. SECOND AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT This Second Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of June 27, 2023, by and b

RCUS / Arcus Biosciences Inc / GILEAD SCIENCES INC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARCUS BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 3, 2023 GILEAD SCIENCES, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 3, 2023 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No

Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 25, 2023

Exhibit 10.1 GILEAD SCIENCES, INC. EMPLOYEE STOCK PURCHASE PLAN (as Amended and Restated January 25, 2023) Termination Date: January 25, 2033 1.Purpose. (a) The purpose of the Employee Stock Purchase Plan (the “Plan”) is to provide a means by which employees of Gilead Sciences, Inc., a Delaware corporation (the “Company”), and its participating Affiliates (as defined in subparagraph 1(c)) may be g

Gilead Sciences, Inc. International Employee Stock Purchase Plan, amended and restated January 25, 2023

Exhibit 10.2 GILEAD SCIENCES, INC. INTERNATIONAL EMPLOYEE STOCK PURCHASE PLAN (as Amended and Restated January 25, 2023) Termination Date: January 25, 2033 1. Purpose. (a) The purpose of the International Employee Stock Purchase Plan (the “Plan”) is to provide a means by which employees of participating Affiliates and Related Entities (both as defined in subparagraph 1(c)), who reside in jurisdict

Form of performance share award agreement - Revenue Goals (U.S.) under 2022 Equity Incentive Plan (for grants made in 2023)

EXHIBIT 10.26 REVENUE PERFORMANCE GOAL GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Performance Share Award

Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants made in 2023)

EXHIBIT 10.33 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit Agreement (this “Agre

Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants made in 2023)

EXHIBIT 10.22 TSR PERFORMANCE GOAL GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Performance Share Award Agr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exa

Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2023)

EXHIBIT 10.11 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Global Stock Option Agreement (this “Agreement”) is

Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (4 year vest)

EXHIBIT 10.52 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit Agreement (this “Agre

Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (3 year vest)

EXHIBIT 10.51 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit Agreement (this “Agre

Offer Letter between Registrant and Deborah Telman, dated June 2, 2022

EXHIBIT 10.49 REVISED June 2, 2022 Deborah Telman Dear Deborah, Gilead Sciences, Inc. (the “Company” or “Gilead”) is pleased to offer you the position of EVP, Corporate Affairs & General Counsel at a grade 37. In this role you will report to Gilead’s Chief Executive Officer (CEO) and Chairman, Daniel O’Day, and will have responsibility for Gilead’s Corporate Affairs & General Counsel Functions. Yo

Global stock option agreement for Deborah Telman under 2022 Equity Incentive Plan

EXHIBIT 10.50 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B.This Global Stock Option Agreement (this “Agreement”) is ex

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sales Increased 59% Year-Over-Year to $67

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 27, 2023 GILEAD SCIENCES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 27, 2023 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

1

April 25, 2023 VIA EDGAR Jenn Do Daniel Gordon U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Re: Gilead Sciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 22, 2023 File No. 0-19731 Dear Ms. Do and Mr. Gordon: This letter responds to the comments of the staff of the Securities

This communication is not a solicitation of proxy authority and no proxy cards will be accepted. Vote your proxies in accordance with the Company’s instructions.

Notice of Exempt Solicitation NAME OF REGISTRANT: Gilead Sciences, Inc. NAME OF PERSON RELYING ON EXEMPTION: Adrian Dominican Sisters ADDRESS OF PERSON RELYING ON EXEMPTION: Judy Byron [email protected] Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of this filer under the terms of the Rule, but is made v

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defi

Gilead Sciences, Inc. (GILD)

Gilead Sciences, Inc. (GILD) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 Gilead Sciences shareholder since 2010 Please consider voting against Mr. Anthony Welters, Chair of the Governance Committee, due to an electioneering phrase on the Gilead Sciences ballot Mr. Welters appears to believe that shareholder proposals do not deserve a fair chance at G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019

EXHIBIT 10.50 Certain information has been excluded from this exhibit pursuant to Item 601(a)(6) of Regulation S-K because disclosure of such information would constitute a clearly unwarranted invasion of personal privacy. The following symbol is included in this exhibit to indicate where such information has been omitted: [*] September 29, 2019 REVISED Merdad Parsey [*] Dear Merdad, Gilead Scienc

Subsidiaries of Registrant

Exhibit 21.1 SUBSIDIARIES OF GILEAD SCIENCES, INC. (as of December 31, 2022) NAME OF SUBSIDIARY COUNTRY OF FORMATION Asegua Therapeutics LLC United States Forty Seven, Inc. United States Forty Seven Holdings, LLC United States Gilead Alberta, LLC United States Gilead Apollo, LLC United States Gilead Biopharmaceutics US LLC United States Gilead Calistoga, LLC United States Gilead Connecticut, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-19731 GILEAD SCIENCES, I

HOOK / Hookipa Pharma Inc / GILEAD SCIENCES INC Passive Investment

SC 13G/A 1 hookipa13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K 100 (CUSIP Number) March 24, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig

GILD / Gilead Sciences, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Gilead Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 375558103 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

GILD / Gilead Sciences, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Gilead Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 375558103 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

GILD / Gilead Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Gilead Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 375558103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Amended and Restated Bylaws of Registrant

Exhibit 3.1 Gilead Sciences, Inc. Amended and Restated Bylaws (as of February 6, 2023) TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 (a) Advance Notice of Stockholder Business 1 (b) Advance Not

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 6, 2023 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fi

ACLX / Arcellx Inc / GILEAD SCIENCES INC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arcellx, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 03940C100 (CUSIP Number) January 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 2, 2023 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022 Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022 Oncology Sales Increased

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022 Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022 Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022 Foster City, CA, February 2, 2023 - Gilead Sciences, Inc.

GILD / Gilead Sciences, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us3755581036013123.txt us3755581036013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) GILEAD SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 375558103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 27, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fi

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion Oncology Sales Increased 79% Year-Over-Year to $57

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): September 12, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission

Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)

EXHIBIT 10.10 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the ?Plan?) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Global Stock Option Agreement (this ?Agreement?) is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exac

Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants made in 2022)

EXHIBIT 10.17 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B.This Stock Option Agreement (this “Agr

Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grants made in 2022

EXHIBIT 10.34 NON-EMPLOYEE DIRECTOR AWARD GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT RECITALS A. The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit

Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)

EXHIBIT 10.32 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT AGREEMENT RECITALS A.The Company maintains the Gilead Sciences, Inc. 2022 Equity Incentive Plan (as the same may be amended, the ?Plan?) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Restricted Stock Unit Agreement (this ?Agree

ALVR / Allovir Inc / GILEAD SCIENCES INC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALLOVIR, INC. (Name of Issuer) Common Stock, $0.0001 per value (Title of Class of Securities) 019818103 (CUSIP Number) July 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 2, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion Oncology Sales Increased 71% Year-Over-Year to $527 million

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 28% Year-Over-Year to $2.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 28, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 25, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File N

As filed with the Securities and Exchange Commission on May 5, 2022

S-8 1 tm2213709d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on May 5, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation or Organiz

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) (2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee Equity Common stoc

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MAY 4, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No

Gilead Sciences, Inc. 2022 Equity Incentive Plan

Exhibit 10.1 GILEAD SCIENCES, INC. 2022 EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company by offering them an opportunity to participate in the Company?s future performance and rewarding them for contributing toward the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exa

Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2022)

EXHIBIT 10.18 TSR PERFORMANCE GOAL GILEAD SCIENCES, INC. 2004 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A. Gilead Sciences, Inc. (the ?Company?) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the ?Plan?) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants to continue their se

Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)

EXHIBIT 10.8 GILEAD SCIENCES, INC. 2004 EQUITY INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT RECITALS A. This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company?s grant of an option to Optionee. B. All capitalized terms used but not otherwise defined in this Agreement shall have the meaning assigned to them in the attached Append

Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2022)

EXHIBIT 10.22 REVENUE PERFORMANCE GOAL GILEAD SCIENCES, INC. 2004 EQUITY INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT RECITALS A.Gilead Sciences, Inc. (the ?Company?) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the ?Plan?) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants to continue their

Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)

EXHIBIT 10.28 GILEAD SCIENCES, INC. 2004 EQUITY INCENTIVE PLAN GLOBAL RESTRICTED STOCK UNIT ISSUANCE AGREEMENT RECITALS A. The Board has adopted the Plan for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Compan

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 28, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 18% Year-Over-Year to $2.2 billion Oncology Sales Increased 60% Year-Over-Year to $420 million

EX-99.1 2 exhibit991earningspressrel.htm EXHIBIT 99.1 GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS Biktarvy Sales Increased 18% Year-Over-Year to $2.2 billion Oncology Sales Increased 60% Year-Over-Year to $420 million Foster City, CA, April 28, 2022 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2022. “Gilead’s performan

NOTICE OF EXEMPT SOLICITATION

PX14A6G 1 b48223px14a6g.htm Non-Confidential 1 NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Gilead Sciences, Inc. NAME OF PERSON RELYING ON EXEMPTION: United Church Funds ADDRESS OF PERSON RELYING ON EXEMPTION: 475 Riverside Dr #1020, New York, NY 10115 Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not require

NOTICE OF EXEMPT SOLICITATION (VOLUNTARY SUBMISSION)

NOTICE OF EXEMPT SOLICITATION (VOLUNTARY SUBMISSION) NAME OF REGISTRANT: Gilead Sciences Inc.

This is not a solicitation of authority to vote your proxy. Please DO NOT send us your proxy card as it will not be accepted Shareholder Proposal for Anticompetitive Practices Report Submitted at Gilead Sciences, Inc

March 25, 2022 This is not a solicitation of authority to vote your proxy. Please DO NOT send us your proxy card as it will not be accepted Shareholder Proposal for Anticompetitive Practices Report Submitted at Gilead Sciences, Inc We are writing to urge Gilead Sciences, Inc shareholders to VOTE FOR Proposal 9 (oversight of risks related to anticompetitive practices) on the Company?s 2022 proxy. T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 gild3988061-def14a.htm DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confident

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

DEFINITIVE PROXY STATEMENT

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 7, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

Gilead TROPiCS-02 Readout Announcement – FAQ 7 March 2022

Exhibit 99.2 Gilead TROPiCS-02 Readout Announcement – FAQ 7 March 2022 Q1. Did PFS meet your bar for clinically meaningful? • There is a broad range of views on what is “clinically meaningful” in this population. We are evaluating the data and will explore potential pathways with regulatory authorities to bring Trodelvy to this group of patients. Q2. You reference TROPiCS-02 clinical activity cons

PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT OF PROGRESSION- FREE SURVIVAL IN LATE-LINE HR+/HER2- METASTATIC BREAST CANCER – Study Will Continue to Follow Patients for Overall Survival, a Key Secondary Endpoint –

Exhibit 99.1 CONTACTS: Jacquie Ross, Investors [email protected] Nathan Kaiser, U.S. Media (650) 522-1853 Karley Ura, Global Media (416) 858-0537 CONFIDENTIAL PHASE 3 TROPiCS-02 STUDY MET THE PRIMARY ENDPOINT OF PROGRESSION- FREE SURVIVAL IN LATE-LINE HR+/HER2- METASTATIC BREAST CANCER ? Study Will Continue to Follow Patients for Overall Survival, a Key Secondary Endpoint ? Foster City,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-19731 GILEAD SCIENCES, I

Subsidiaries of Registrant

Exhibit 21.1 SUBSIDIARIES OF GILEAD SCIENCES, INC. (as of December 31, 2021) NAME OF SUBSIDIARY COUNTRY OF FORMATION Asegua Therapeutics LLC United States Forty Seven, Inc. United States Forty Seven Holdings, LLC United States Gilead Alberta, LLC United States Gilead Apollo, LLC United States Gilead Biopharmaceutics US LLC United States Gilead Calistoga, LLC United States Gilead Connecticut, Inc.

HOOK / Hookipa Pharma Inc / GILEAD SCIENCES INC Passive Investment

SC 13G/A 1 hookipa13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 3)* HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 43906K 100 (CUSIP

AGEN / Agenus Inc / GILEAD SCIENCES INC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Agenus Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00847G705 (CUSIP Number) December 31, 2021 (Date of Ev

GILD / Gilead Sciences, Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Gilead Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 375558103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

ALLO / Allogene Therapeutics Inc / GILEAD SCIENCES INC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Allogene Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 019770106 (CUSIP Number) April 20, 20

SRRA / Sierra Oncology Inc / GILEAD SCIENCES INC Passive Investment

SC 13G/A 1 sierra13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Sierra Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 82640U404 (CUSIP

GILD / Gilead Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Gilead Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 375558103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

AGEN / Agenus Inc / GILEAD SCIENCES INC Passive Investment

SC 13G 1 agenus13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Agenus Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 00847G705 (CUSIP Number) Decemb

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 1, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fi

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Biktarvy Sales Increased Year-Over-Year by 19% for Full Year 2021 & 22% for Fourth Quarter 2021 EPS Results Reflect $1.25 Billion Charge for a Legal Settlement & $625 Milli

GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Biktarvy Sales Increased Year-Over-Year by 19% for Full Year 2021 & 22% for Fourth Quarter 2021 EPS Results Reflect $1.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 1, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 5, 2022 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 28, 2021 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission Fi

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS 2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter Biktarvy Sales Increased 20% Year-Over-Year to Record $2.3 Billion

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS 2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter Biktarvy Sales Increased 20% Year-Over-Year to Record $2.

TNGX / Tango Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TANGO THERAPEUTICS, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) August 10, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exac

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS Second Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury Biktarvy Sales Increased 24% Year-Over-Year

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS Second Quarter 2021 Product Sales Increased 21% Year-Over-Year Primarily Driven by Veklury Biktarvy Sales Increased 24% Year-Over-Year Foster City, CA, July 29, 2021 - Gilead Sciences, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 29, 2021 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MAY 12, 2021 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File N

Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021)

EX-10.16 3 gildq12021ex10162021psuagr.htm 2021 PSU AGREEMENT-TSR GOALS EXHIBIT 10.16 TSR PERFORMANCE GOAL GILEAD SCIENCES, INC. PERFORMANCE SHARE AWARD AGREEMENT RECITALS A. Gilead Sciences, Inc. (the “Company”) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the “Plan”) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Di

Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021)

EXHIBIT 10.7 GILEAD SCIENCES, INC. GLOBAL STOCK OPTION AGREEMENT RECITALS A. This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company’s grant of an option to Optionee. B. All capitalized terms used but not otherwise defined in this Agreement shall have the meaning assigned to them in the attached Appendix. NOW, THEREFORE, the Com

Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2021)

EXHIBIT 10.19 REVENUE PERFORMANCE GOAL GILEAD SCIENCES, INC. PERFORMANCE SHARE AWARD AGREEMENT RECITALS A.Gilead Sciences, Inc. (the ?Company?) has implemented the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the ?Plan?) for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants to continue their service relationship with

Quarterly Report - FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exa

Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021)

EXHIBIT 10.24 GILEAD SCIENCES, INC. GLOBAL RESTRICTED STOCK UNIT ISSUANCE AGREEMENT RECITALS A. The Board has adopted the Plan for the purpose of providing incentives to attract, retain and motivate eligible Employees, Directors and Consultants. B. This Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company’s issuance of shares of C

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 29, 2021 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS First Quarter 2021 Product Sales Increased 16% Year-Over-Year Primarily Driven by Veklury Returned $1.2 Billion of Cash to Shareholders in First Quarter 2021 Through Dividends and Share R

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS First Quarter 2021 Product Sales Increased 16% Year-Over-Year Primarily Driven by Veklury Returned $1.

-

PX14A6G 1 p416218px14a6g.htm Non-Confidential 1 NOTICE OF EXEMPT SOLICITATION NAME OF REGISTRANT: Gilead Sciences, Inc. NAME OF PERSON RELYING ON EXEMPTION: United Church Funds ADDRESS OF PERSON RELYING ON EXEMPTION: 475 Riverside Dr #1020, New York, NY 10115 NAME OF PERSON RELYING ON EXEMPTION: Mercy Investment Services ADDRESS OF PERSON RELYING ON EXEMPTION: 2039 N. Geyer Road, St. Louis, MO 631

- DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14

DEFINITIVE PROXY STATEMENT

Subsidiaries of Registrant

Exhibit 21.1 SUBSIDIARIES OF GILEAD SCIENCES, INC. (as of December 31, 2020) NAME OF SUBSIDIARY COUNTRY OF FORMATION Asegua Therapeutics LLC United States Forty Seven, Inc. United States Forty Seven Holdings, LLC United States Gilead Alberta, LLC United States Gilead Apollo, LLC United States Gilead Biopharmaceutics US LLC United States Gilead Calistoga, LLC United States Gilead Connecticut, Inc.

Annual Report - FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-19731 GILEAD SCIENCES, INC

Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017

EX-10.2 2 gild20ormex102amendmentto2.htm 2004 EQUITY INCENTIVE PLAN AMENDMENT NO. 1 (AMENDED AND RESTATED MAY 10, 2017) EXHIBIT 10.2 AMENDMENT NO. 1 TO GILEAD SCIENCES, INC. 2004 EQUITY INCENTIVE PLAN AS AMENDED AND RESTATED MAY 10, 2017 This AMENDMENT NO. 1 (this “Amendment”) to the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended and restated May 10, 2017 (the “Plan”) of Gilead Scien

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Gilead Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 375558103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Gilead Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 375558103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) HOOKIPA PHARMA INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 43906K 100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Gilead Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 375558103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: